Q3 2025 Uniqure NV Earnings Call Transcript
Key Points
- uniQure NV (QURE) announced positive top line data from its pivotal Phase I/II study of AMT-130 in Huntington's disease, showing statistically significant slowing of disease progression.
- The high dose of AMT-130 demonstrated a 75% slowing of disease progression over three years, meeting the primary endpoint of the study.
- AMT-130 also showed a 60% slowing of disease progression in a key secondary endpoint, total functional capacity, at three years.
- The company reported promising initial data from AMT-260 for mesial temporal lobe epilepsy, with a reduction in seizure frequency and no serious adverse events.
- uniQure NV (QURE) has a strong financial position with cash, cash equivalents, and investment securities totaling $649.2 million, expected to fund operations into 2029.
- The FDA no longer agrees that the data from the Phase I/II studies of AMT-130 is adequate to support a BLA submission, introducing uncertainty in the approval timeline.
- uniQure NV (QURE) has paused enrollment in the Phase I/II EPISOD1 trial of AMT-162 for SOD1 ALS due to a dose-limiting toxicity observed in one patient.
- Research and development expenses increased by $3.8 million compared to the same period in 2024, driven by costs related to the BLA submission preparation for AMT-130.
- Selling, general, and administrative expenses rose by $7.8 million, primarily due to increased employee-related expenses and professional fees.
- The company has not yet engaged with regulatory agencies in the UK or EU for AMT-130, focusing primarily on the FDA, which may delay international submissions.
Good morning, and welcome to Uniqure's third-quarter 2025 earnings call. (Operator Instructions) As a reminder, this conference call is being recorded.
I would now like to turn the call over to Chiara Russo, Senior Director of Investor Relations. Thank you. Please go ahead.
Good morning, and thank you for joining us for Uniqure's third-quarter of 2025 earnings call. Earlier this morning, Uniqure released its financial results for the third-quarter of 2025, and our press release is available on the Investors & Media section of our website at uniqure.com. Our 10-Q was also filed with the SEC earlier today.
Joining me on the call this morning are Matt Kapusta, Chief Executive Officer; Dr. Walid Abi-Saab, Chief Medical Officer; Kylie O'Keefe, Chief Customer and Strategy Officer; and Christian Klemt, Chief Financial Officer. After our formal remarks, we'll open the call up for Q&A.
Before we begin, please note that we will be making forward-looking statements during this investor call
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
